# 2026-09268: FDA's New Rules: Checking if Pills Play Nice with Pregnancies

2026-09268, Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-11, effective 2026-05-11; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09268
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09268
- Title: Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25579
- Published: 2026-05-11
- Effective: 2026-05-11
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA's New Rules: Checking if Pills Play Nice with Pregnancies

## Summary

The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Postapproval Pregnancy Safety Studies." The purpose of this guidance will be to provide sponsors and investigators with recommendations on how to design investigations to assess the outcomes in pregnant women exposed to drug and biological products regulated by FDA (i.e., pregnancy safety studies) in the postapproval setting. This guidance finalizes the draft guidance of the same name issued on May 9, 2019.

## Effects PRIA read

- Final FDA Guidance for Pregnancy Safety Studies: benefit, low. On May 11, 2026 the FDA published a final guidance called "Postapproval Pregnancy Safety Studies" that gives recommendations to drug sponsors and investigators on how to design studies that assess safety outcomes in pregnant women after a drug or biologic is approved. The guidance finalizes a draft…
- New Method Guidance: Registries & Rare Exposures: benefit, medium. The final guidance updates methods for postapproval pregnancy safety work by clarifying the pregnancy registry section (including a new statistical methods subsection), broadening complementary study methods, expanding discussion on collecting data when rare exposures are expected, and updating ter…
- Guidance Is Non-Binding and Deregulatory: benefit, low. FDA states the guidance reflects its current thinking but is not binding; sponsors may use alternative approaches if they meet statute and regulation requirements. FDA also assessed this action as an Executive Order 14192 deregulatory action and the guidance contains no new collections of informati…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09268 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09268/postapproval-pregnancy-safety-studies-guidance-for-industry-availability)
- [2026-09268 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09268.pdf)

## Related
- [Previous: 2026-09267, Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction o…](https://policyrisk.com/federal-register/2026-09267)
- [Next: 2026-09269, Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry;…](https://policyrisk.com/federal-register/2026-09269)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09268 (as of 2026-06-08).
